CA Patent

CA2642656A1 — System for delivering nebulized cyclosporine and methods of treatment

Assigned to Novartis Pharma AG · Expires 2007-09-07 · 19y expired

What this patent protects

Systems comprising a pressurized delivery device and a formulation of cyclosporine coupled to an exhalation filter or trap that is capable of preventing cyclosporine from escaping into the local environment are provided. An apparatus for use in the system comprises either an exha…

USPTO Abstract

Systems comprising a pressurized delivery device and a formulation of cyclosporine coupled to an exhalation filter or trap that is capable of preventing cyclosporine from escaping into the local environment are provided. An apparatus for use in the system comprises either an exhalation filter and a pressurized delivery device, wherein the exhalation filter is capable of providing high filter efficiency and maintaining low filter resistance after usage with the formulation, or a trap which provides a means for expired gas to be released into a solvent chamber containing a solvent with a high affinity for cyclosporine. These systems may be used to treat patients with pulmonary disorders, organ transplant patients such as lung transplant patients, and other immune-related disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2642656A1
Jurisdiction
CA
Classification
Expires
2007-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.